NF-kappa B Inhibitors - Pipeline Insight, 2022

January 2022 | 90 pages | ID: DDC28B8BB46EN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight’s, “NF-kappa B Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in NF-kappa B Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

NF-kappa B Inhibitors Understanding

NF-kappa B Inhibitors: Overview

NF-kappa B, are Nuclear Factor kappa light chain enhancer of activated B cells, comprises a family of inducible transcription factors. NF-kB is a short name of Nuclear Factor kappa-light-chain-enhancer of activated B cells. NF-kB molecular are usually dimers. A typical structure of NF-kB is the P50-P65 dimer (NF-kB1/RelA).

Function - NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumor genesis, and apoptosis. NF-kappa-B regulates DNA transcription, cytokine production, cell survival, and other important cell events, especially play a key role in regulating the immune response to infection.

NF-kappa B Inhibitors - Abnormal NF-kB signaling results in human diseases, such as immune disorders, inflammation, and various cancers. An aberrant NF-kappaB activation is associated with cancer development and contributes to the pathogenesis of chronic inflammatory diseases like rheumatoid arthritis (RA) and multiple sclerosis (MS). NF-?B signaling pathway provides a desirable target for therapeutic development. These inhibitors include various natural products, chemicals, metals, metabolites, synthetic compounds, peptides, proteins (cellular, viral, bacterial, fungal), and physical conditions.

NF-kappa B Inhibitors Emerging Drugs Chapters

This segment of the NF-kappa B Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

NF-kappa B Inhibitors Emerging Drugs

• MK-7110: Merck

MK-7110 (formerly CD24Fc) is a potentially first-in-class recombinant fusion protein that targets the innate immune system. It is in Phase III clinical trials for the prophylactic treatment of graft-versus-host disease (GVHD) that preserves or enhances the graft-versus-leukemia (GVL) effect in patients with leukemia undergoing hematopoietic stem cell transplantation (HSCT). MK-7110 comprises the nonpolymorphic regions of CD24 attached to the Fc region of human IgG1. The company has received Orphan Drug designation for CD24Fc in the US and Europe.

• NE3107: NeurMedix

NE3107 – an orally bioavailable, small molecule produced by chemical synthesis – was initially discovered by Hollis-Eden Pharmaceuticals and selected for clinical development to treat inflammatory diseases in humans in 2006 under the product code HE3286. Currently, NeurMedix is developing NE3107 as a therapeutic for neurological disorders in which neuroinflammation is a major contributing factor.

• AMG 0101 (NF-?B Decoy Oligodeoxynucleotide): AnGes

NF-?B Decoy Oligodeoxynucleotide is a decoy oligo with the same genetic sequence as the NF-?B-binding site. As it targets the transcription factor itself, it is expected to have superior efficacy and milder side effects than conventional drugs due to its specificity and definite effects on the molecular target. AnGes is developing therapeutic agents based on its properties to treat patients suffering from atopic dermatitis, rheumatic arthritis, and restenosis – conditions caused by the excessive immunological response. It is currently in Phase III stage of development for Atopic dermatitis and Phase I for Chronic discogenic lumber back pain.

• CXA-10: Complexa

CXA-10 is an oral nitrated fatty acid (NFA) that impacts the fibrotic and inflammatory pathways. The drug acts through key reparative, metabolic and inflammatory pathways, including upregulation of the Nrf2 pathway and inhibition of nuclear factor-kappa B. In addition, it increases the expression of heat shock proteins, which act as chaperones during cellular stress. In six Phase I clinical trials, CXA-10 demonstrated target engagement and was shown to be tolerable and safe in more than 100 subjects. Importantly, it has shown an impact on relevant biomarkers of pharmacological action as well as inhibition of crucial biomarkers of disease-related inflammation and fibrosis.

• Imx-110: Immix Biopharma

Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. It contains NF-kB/Stat3/pan-kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties, allowing it to deliver even more payload to tumors or other cell populations of interest if needed. Imx-110 has shown preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models – with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin alone and a wholesale shift in the tumor microenvironment post-administration.

Further product details are provided in the report……..

NF-kappa B Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different NF-kappa B Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on NF-kappa B Inhibitors

There are approx. 10+ key companies which are developing the NF-kappa B Inhibitors. The companies which have their NF-kappa B Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Merck.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

NF-kappa B Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Topical
• Oral
• Intravenous
• Parenteral
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Gene Therapies
• Peptides
• Oligonucleotides
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NF-kappa B Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses NF-kappa B Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NF-kappa B Inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence NF-kappa B Inhibitors R&D. The therapies under development are focused on novel approaches for NF-kappa B Inhibitors.

NF-kappa B Inhibitors Report Insights

• NF-kappa B Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

NF-kappa B Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing NF-kappa B Inhibitors drugs?
• How many NF-kappa B Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for NF-kappa B Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NF-kappa B Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for NF-kappa B Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck
• NeurMedix
• AnGes
• Complexa
• GeneOne Life Science
• Accendatech
• Link Health Group
• Immix Biopharma
• First Wave Bio
• IMMD
• ILIAS Biologics

Key Products

• MK-7110
• NE3107
• AMG 0101
• CXA-10
• GLS-1027
• ACT001
• LH-025
• IMX-110
• FW 424
• IMD-2560
• ILB-202

Contents

Introduction
Executive Summary
NF-kappa B Inhibitors: Overview
  Structure
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
  Comparative Analysis
MK-7110: Merck
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
GLS-1027: GeneOne Life Science
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
  Comparative Analysis
IMX-110: Immix Biopharma
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
IMD-2560: IMMD
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  Comparative Analysis
ILB-202: ILIAS Biologics
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
NF-kappa B Inhibitors Key Companies
NF-kappa B Inhibitors Key Products
NF-kappa B Inhibitors- Unmet Needs
NF-kappa B Inhibitors- Market Drivers and Barriers
NF-kappa B Inhibitors- Future Perspectives and Conclusion
NF-kappa B Inhibitors Analyst Views
NF-kappa B Inhibitors Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for NF-kappa B Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for NF-kappa B Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products